# Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer

> **NCT02422979** · PHASE1,PHASE2 · COMPLETED · sponsor: **Rakuten Medical, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Recurrent Head and Neck Cancer

## Interventions

- **COMBINATION_PRODUCT:** PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2
- **COMBINATION_PRODUCT:** PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2
- **COMBINATION_PRODUCT:** PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2
- **COMBINATION_PRODUCT:** PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
- **COMBINATION_PRODUCT:** PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
- **COMBINATION_PRODUCT:** PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2

## Key facts

- **NCT ID:** NCT02422979
- **Lead sponsor:** Rakuten Medical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2019-02-25
- **Final completion:** 2019-02-25
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02422979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02422979, "Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02422979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*